Treatment for GTD is very successful and more than 98% of women with these conditions are cured. There aren't often trials looking into the treatment of GTDs. This is mainly because they are such rare tumours and current treatments work so well.
Why research is done
All treatments have to be fully researched before they can be adopted as standard treatment for everyone. This is so that:
- we can be sure they work
- we can be sure they work better than the treatments that are available at the moment
- they are known to be safe
Firstly, treatments are developed and tested in laboratories. For ethical and safety reasons, experimental treatments must be tested in the laboratory before they can be tried in patients. If a treatment described here is said to be at the laboratory stage of research, it is not ready for patients and is not available either within or outside the NHS. Cancer Research UK supports a lot of UK laboratory research into cancer.
Tests in patients are called clinical trials. Cancer Research UK supports many UK and international clinical trials.
Research into treatment for GTD
Treatment for GTD is very successful and more than 98% of women with these conditions are cured. But doctors are still looking into how they can improve treatment.
A recent trial that closed in 2016 looked at comparing 2 chemotherapy drugs used to treat GTD called actinomycin D and methotrexate. They wanted to see which works better to control GTD and causes the fewest side effects.